

Presentation at American College of Rheumatology (ACR) Convergence 2023 of positive izokibep long-term data from Phase 2 study

Solna, Sweden, November 13, 2023. Affibody today announced that positive long-term data from a Phase 2 trial of izokibep in Psoriatic Arthritis (PsA) will be presented at the ACR Convergence 2023, November 10-15, 2023, San Diego, USA.

46-week results from the Phase 2 trial of izokibep in PsA were announced on April 11, 2023, with continued improvement of responses including >75% of patients achieving ACR50, >50% of patients achieving ACR70, >70% of patients achieving PASI100, >80% of patients achieving resolution of enthesitis as measured by the Leeds Enthesitis Index (LEI), and >50% of patients achieving Minimal Disease Activity (MDA), an important composite measure of overall disease impact. These clinical responses further increased Quality of Life (QoL) for patients, with the majority of patients showing important improvements in disease burden as measured by the PsAID, a validated psoriatic arthritis-specific patient reported outcome measure.

Dr. Peter Taylor and Dr. Philip Mease will present these and additional clinical measures of disease resolution and QoL in a poster session and oral podium presentation, respectively, at the ACR Convergence 2023 on Monday, November 13, 2023.

The title of the poster is: *Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 – Phase 2 RCT Results.*

The title of the oral presentation is: *Izokibep Demonstrates Major Disease Control on ACR70, PASI100 and Enthesitis Resolution in Patients with Active Psoriatic Arthritis Treated Through 46 Weeks.*

Additional information about ACR Convergence 2023 is available at: <https://rheumatology.org/annual-meeting>.

Attachments

[Presentation at American College of Rheumatology \(ACR\) Convergence 2023 of positive izokibep long-term data from Phase 2 study](#)